{"result": "{\n    \"title\": \"GeparQuinto Community\",\n    \"summary\": \"The GeparQuinto community revolves around the GeparQuinto clinical trial, which investigated the effectiveness of neoadjuvant chemotherapy with trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer. The community consists of researchers, authors, and organizations involved in the trial, including Von Minckwitz G, Untch M, Loibl S, and GBG 44.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for significant findings and implications for breast cancer treatment.\",\n    \"findings\": [\n        {\n            \"summary\": \"GeparQuinto Clinical Trial\",\n            \"explanation\": \"The GeparQuinto clinical trial is a randomized phase 3 study that investigated the effectiveness of neoadjuvant chemotherapy with trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer. The trial was conducted by GBG 44 and involved multiple researchers, including Von Minckwitz G, Untch M, and Loibl S. [Data: Entities (173, 730, 464, 722, 733); Relationships (239, 247, 233, 244, 228, +more)].\"\n        },\n        {\n            \"summary\": \"Researchers Involved\",\n            \"explanation\": \"The GeparQuinto community consists of multiple researchers, including Von Minckwitz G, Untch M, Loibl S, and Rezai M, who have contributed to the trial and its findings. These researchers have published multiple papers and studies on the topic of breast cancer and neoadjuvant chemotherapy. [Data: Entities (173, 730, 464, 722, 733); Relationships (239, 247, 233, 244, 228, +more)].\"\n        },\n        {\n            \"summary\": \"Organizations Involved\",\n            \"explanation\": \"The GeparQuinto community involves multiple organizations, including GBG 44, which conducted the clinical trial. Other organizations, such as J Clin Oncol and Lancet Oncol, have published papers on the trial's findings. [Data: Entities (173, 730, 464, 722, 733); Relationships (239, 247, 233, 244, 228, +more)].\"\n        },\n        {\n            \"summary\": \"Findings and Implications\",\n            \"explanation\": \"The GeparQuinto trial has significant findings and implications for breast cancer treatment. The study's results suggest that neoadjuvant chemotherapy with trastuzumab or lapatinib may be effective in treating patients with human epidermal growth factor receptor 2-positive breast cancer. [Data: Entities (173, 730, 464, 722, 733); Relationships (239, 247, 233, 244, 228, +more)].\"\n        },\n        {\n            \"summary\": \"Co-Authorship\",\n            \"explanation\": \"Multiple researchers have co-authored papers and studies on the topic of breast cancer and neoadjuvant chemotherapy. This co-authorship suggests a high level of collaboration and expertise within the GeparQuinto community. [Data: Entities (173, 730, 464, 722, 733); Relationships (590, 400, 601, 404, 608, +more)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n173,\"\"\"GEPARQUINTO\"\"\",\"Here is a comprehensive summary of the data:\n\nGeparQuinto is a randomized neoadjuvant phase 3 clinical trial that investigated the effectiveness of neoadjuvant chemotherapy with trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer. Specifically, the trial compared lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy to determine their relative efficacy in this patient population.\",21\r\n730,\"\"\"VON MINCKWITZ G\"\"\",\"Here is a comprehensive summary of the data:\n\nVon Minckwitz G is a researcher who has been involved in several studies and publications. Specifically, they have contributed to a study on neoadjuvant carboplatin in early breast cancer, and were also a part of the GeparQuinto study. Additionally, von Minckwitz G has authored a medical study and a research paper, demonstrating their expertise and contributions to the field of breast cancer research.\",9\r\n464,\"\"\"UNTCH M\"\"\",\"Here is a comprehensive summary of the data:\n\n\"\"Untch M\"\" is an author of multiple medical studies and research papers. Specifically, they are the author of a research paper on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy, as well as a study on breast cancer. Additionally, they have authored a general research paper.\",8\r\n722,\"\"\"LOIBL S\"\"\",\"Here is a comprehensive summary of the data:\n\nLoibl S is a researcher who has been involved in several studies and research papers. Specifically, Loibl S is a researcher involved in a study on neoadjuvant carboplatin in early breast cancer, and also participated in the GeparQuinto study. Additionally, Loibl S is an author of a research paper on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy, and has also authored a research paper in general.\n\nNote: I did not include the empty quotes in the description as they do not provide any meaningful information.\",4\r\n733,\"\"\"REZAI M\"\"\",\"Here is a comprehensive summary of the data:\n\nRezai M is a researcher who has been involved in several studies and projects. Specifically, they have been involved in a study on neoadjuvant carboplatin in early breast cancer, as well as the GeparQuinto study. Additionally, Rezai M has authored a research paper, demonstrating their expertise and contributions to the field of research.\",3\r\n723,\"\"\"BISCHOFF J\"\"\",\"Here is a comprehensive summary of the data:\n\nBischoff J is a researcher who has been involved in the GeparQuinto study. Additionally, Bischoff J is an author of a research paper that compares lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy.\",2\r\n726,\"\"\"BLOHMER JU\"\"\",\"Here is a comprehensive summary of the data:\n\nBlohmer JU is a researcher involved in the GeparQuinto study and has also authored a research paper on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy.\",2\r\n724,\"\"\"EIDTMANN H\"\"\",\"Here is a comprehensive summary of the data:\n\nEidtmann H is a researcher who has been involved in the GeparQuinto study. Additionally, Eidtmann H is an author of a research paper that compares lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy.\",2\r\n725,\"\"\"KAUFMANN M\"\"\",\"Here is a comprehensive summary of the data:\n\nKaufmann M is a researcher who has been involved in the GeparQuinto study and has also authored a research paper on the topic of lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy.\",2\r\n735,\"\"\"BOUSSEN H\"\"\",\"\"\"Boussen H is a researcher involved in the GeparQuinto study.\"\"\",1\r\n737,\"\"\"DESILVIO M\"\"\",\"Here is a comprehensive summary of the data:\n\nDeSilvio M is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.\",1\r\n734,\"\"\"FASCHING PA\"\"\",\"\"\"Fasching PA is a researcher involved in the GeparQuinto study.\"\"\",1\r\n740,\"\"\"G5\"\"\",\"\"\"G5 is a study evaluating the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.\"\"\",1\r\n728,\"\"\"GBG 44\"\"\",\"Here is a comprehensive summary of the data:\n\nGBG 44 is a clinical trial that investigated the efficacy of lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy. Additionally, GBG 44 is the organization responsible for conducting the GeparQuinto study.\",1\r\n731,\"\"\"GERBER B\"\"\",\"\"\"Gerber B is a researcher involved in the GeparQuinto study.\"\"\",1\r\n732,\"\"\"SCHEM C\"\"\",\"\"\"Schem C is a researcher involved in the GeparQuinto study.\"\"\",1\r\n736,\"\"\"ZAKS T\"\"\",\"Here is a comprehensive summary of the data:\n\nZaks T is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.\",1\r\n738,\"\"\"SALAZAR V\"\"\",\"Here is a comprehensive summary of the data:\n\nSalazar V is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.\",1\r\n739,\"\"\"SPECTOR N\"\"\",\"Here is a comprehensive summary of the data:\n\nSPECTOR N is a researcher who has been involved in the GeparQuinto study and has also authored a study on neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.\",1\r\n462,\"\"\"CORTAZAR P\"\"\",\"\"\"Cortazar P is an author of a study on breast cancer.\"\"\",5\r\n874,\"\"\"DENKERT C\"\"\",\"Here is a comprehensive summary of the data:\n\nDenkert C is a researcher who has been involved in a study on neoadjuvant carboplatin in early breast cancer. Additionally, Denkert C is an author of a research paper, likely related to the study on neoadjuvant carboplatin in early breast cancer.\",2\r\n873,\"\"\"SALAT C\"\"\",\"Here is a comprehensive summary of the data:\n\nSalat C is a researcher who has been involved in a study on neoadjuvant carboplatin in early breast cancer. Additionally, Salat C is an author of a research paper, likely related to the study on neoadjuvant carboplatin in early breast cancer.\",2\r\n777,\"\"\"DE AZAMBUJA E\"\"\",\"\"\"de Azambuja E is an author of a medical study.\"\"\",1\r\n769,\"\"\"MANO MS\"\"\",\"\"\"Mano MS is an author of a research paper.\"\"\",1\r\n776,\"\"\"PROCTER M\"\"\",\"\"\"Procter M is an author of a medical study.\"\"\",1\r\n770,\"\"\"MAMOUNAS EP\"\"\",\"Here is the comprehensive summary:\n\nMamounas EP is a researcher who has authored multiple medical studies and research papers.\",1\r\n463,\"\"\"ZHANG L\"\"\",\"\"\"Zhang L is an author of a study on breast cancer.\"\"\",1\r\n465,\"\"\"MEHTA K\"\"\",\"\"\"Mehta K is an author of a study on breast cancer.\"\"\",1\r\n466,\"\"\"COSTANTINO JP\"\"\",\"\"\"Costantino JP is an author of a study on breast cancer.\"\"\",1\r\n467,\"\"\"WOLMARK N\"\"\",\"\"\"Wolmark N is an author of a study on breast cancer.\"\"\",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n239,\"\"\"GEPARQUINTO\"\"\",\"\"\"CRISTOFANILLI M\"\"\",\"\"\"Cristofanilli M is a researcher involved in the GeparQuinto study.\"\"\",39\r\n247,\"\"\"GEPARQUINTO\"\"\",\"\"\"J CLIN ONCOL\"\"\",\"\"\"GeparQuinto is published in J Clin Oncol.\"\"\",31\r\n233,\"\"\"GEPARQUINTO\"\"\",\"\"\"VON MINCKWITZ G\"\"\",\"\"\"von Minckwitz G is a researcher involved in the GeparQuinto study.\"\"\",30\r\n244,\"\"\"GEPARQUINTO\"\"\",\"\"\"UNTCH M\"\"\",\"\"\"Untch M is a researcher involved in the GeparQuinto study.\"\"\",29\r\n228,\"\"\"GEPARQUINTO\"\"\",\"\"\"LOIBL S\"\"\",\"\"\"Loibl S is a researcher involved in the GeparQuinto study.\"\"\",25\r\n236,\"\"\"GEPARQUINTO\"\"\",\"\"\"REZAI M\"\"\",\"\"\"Rezai M is a researcher involved in the GeparQuinto study.\"\"\",24\r\n246,\"\"\"GEPARQUINTO\"\"\",\"\"\"LANCET ONCOL\"\"\",\"\"\"GeparQuinto is published in Lancet Oncol.\"\"\",24\r\n229,\"\"\"GEPARQUINTO\"\"\",\"\"\"BISCHOFF J\"\"\",\"\"\"Bischoff J is a researcher involved in the GeparQuinto study.\"\"\",23\r\n232,\"\"\"GEPARQUINTO\"\"\",\"\"\"BLOHMER JU\"\"\",\"\"\"Blohmer JU is a researcher involved in the GeparQuinto study.\"\"\",23\r\n230,\"\"\"GEPARQUINTO\"\"\",\"\"\"EIDTMANN H\"\"\",\"\"\"Eidtmann H is a researcher involved in the GeparQuinto study.\"\"\",23\r\n231,\"\"\"GEPARQUINTO\"\"\",\"\"\"KAUFMANN M\"\"\",\"\"\"Kaufmann M is a researcher involved in the GeparQuinto study.\"\"\",23\r\n238,\"\"\"GEPARQUINTO\"\"\",\"\"\"BOUSSEN H\"\"\",\"\"\"Boussen H is a researcher involved in the GeparQuinto study.\"\"\",22\r\n241,\"\"\"GEPARQUINTO\"\"\",\"\"\"DESILVIO M\"\"\",\"\"\"DeSilvio M is a researcher involved in the GeparQuinto study.\"\"\",22\r\n237,\"\"\"GEPARQUINTO\"\"\",\"\"\"FASCHING PA\"\"\",\"\"\"Fasching PA is a researcher involved in the GeparQuinto study.\"\"\",22\r\n248,\"\"\"GEPARQUINTO\"\"\",\"\"\"G5\"\"\",\"\"\"G5 is a study related to GeparQuinto.\"\"\",22\r\n245,\"\"\"GEPARQUINTO\"\"\",\"\"\"GBG 44\"\"\",\"\"\"GeparQuinto is conducted by GBG 44.\"\"\",22\r\n234,\"\"\"GEPARQUINTO\"\"\",\"\"\"GERBER B\"\"\",\"\"\"Gerber B is a researcher involved in the GeparQuinto study.\"\"\",22\r\n235,\"\"\"GEPARQUINTO\"\"\",\"\"\"SCHEM C\"\"\",\"\"\"Schem C is a researcher involved in the GeparQuinto study.\"\"\",22\r\n240,\"\"\"GEPARQUINTO\"\"\",\"\"\"ZAKS T\"\"\",\"\"\"Zaks T is a researcher involved in the GeparQuinto study.\"\"\",22\r\n242,\"\"\"GEPARQUINTO\"\"\",\"\"\"SALAZAR V\"\"\",\"\"\"Salazar V is a researcher involved in the GeparQuinto study.\"\"\",22\r\n243,\"\"\"GEPARQUINTO\"\"\",\"\"\"SPECTOR N\"\"\",\"\"\"Spector N is a researcher involved in the GeparQuinto study.\"\"\",22\r\n590,\"\"\"SCHNEEWEISS A\"\"\",\"\"\"VON MINCKWITZ G\"\"\",\"Here is a comprehensive summary of the data:\n\nSCHNEEWEISS A and VON MINCKWITZ G are co-authors of a research paper and a study on neoadjuvant carboplatin in early breast cancer.\n\nNote: I have concatenated the descriptions to provide a single, comprehensive summary, and resolved any potential contradictions to ensure a coherent output.\",17\r\n400,\"\"\"CORTAZAR P\"\"\",\"\"\"UNTCH M\"\"\",\"\"\"Cortazar P and Untch M are co-authors of a study on breast cancer.\"\"\",13\r\n601,\"\"\"LOIBL S\"\"\",\"\"\"VON MINCKWITZ G\"\"\",\"\"\"von Minckwitz G and Loibl S are co-authors of a research paper.\"\"\",13\r\n404,\"\"\"UNTCH M\"\"\",\"\"\"LOIBL S\"\"\",\"Here is a comprehensive summary of the data:\n\nLoibl S and Untch M are co-authors of a medical study and a research paper on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy.\",12\r\n608,\"\"\"VON MINCKWITZ G\"\"\",\"\"\"REZAI M\"\"\",\"\"\"von Minckwitz G and Rezai M are co-authors of a research paper.\"\"\",12\r\n607,\"\"\"VON MINCKWITZ G\"\"\",\"\"\"DENKERT C\"\"\",\"\"\"von Minckwitz G and Denkert C are co-authors of a research paper.\"\"\",11\r\n606,\"\"\"VON MINCKWITZ G\"\"\",\"\"\"SALAT C\"\"\",\"\"\"von Minckwitz G and Salat C are co-authors of a research paper.\"\"\",11\r\n405,\"\"\"UNTCH M\"\"\",\"\"\"BISCHOFF J\"\"\",\"\"\"Untch M and Bischoff J are co-authors of a research paper on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy.\"\"\",10\r\n408,\"\"\"UNTCH M\"\"\",\"\"\"BLOHMER JU\"\"\",\"\"\"Untch M and Blohmer JU are co-authors of a research paper on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy.\"\"\",10\r\n605,\"\"\"VON MINCKWITZ G\"\"\",\"\"\"DE AZAMBUJA E\"\"\",\"\"\"von Minckwitz G and de Azambuja E are co-authors of a medical study.\"\"\",10\r\n406,\"\"\"UNTCH M\"\"\",\"\"\"EIDTMANN H\"\"\",\"\"\"Untch M and Eidtmann H are co-authors of a research paper on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy.\"\"\",10\r\n407,\"\"\"UNTCH M\"\"\",\"\"\"KAUFMANN M\"\"\",\"\"\"Untch M and Kaufmann M are co-authors of a research paper on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy.\"\"\",10\r\n603,\"\"\"VON MINCKWITZ G\"\"\",\"\"\"MANO MS\"\"\",\"\"\"von Minckwitz G and Mano MS are co-authors of a research paper.\"\"\",10\r\n604,\"\"\"VON MINCKWITZ G\"\"\",\"\"\"PROCTER M\"\"\",\"\"\"von Minckwitz G and Procter M are co-authors of a medical study.\"\"\",10\r\n409,\"\"\"UNTCH M\"\"\",\"\"\"MAMOUNAS EP\"\"\",\"\"\"Mamounas EP and Untch M are co-authors of a research paper.\"\"\",9\r\n399,\"\"\"CORTAZAR P\"\"\",\"\"\"ZHANG L\"\"\",\"\"\"Cortazar P and Zhang L are co-authors of a study on breast cancer.\"\"\",6\r\n401,\"\"\"CORTAZAR P\"\"\",\"\"\"MEHTA K\"\"\",\"\"\"Cortazar P and Mehta K are co-authors of a study on breast cancer.\"\"\",6\r\n402,\"\"\"CORTAZAR P\"\"\",\"\"\"COSTANTINO JP\"\"\",\"\"\"Cortazar P and Costantino JP are co-authors of a study on breast cancer.\"\"\",6\r\n403,\"\"\"CORTAZAR P\"\"\",\"\"\"WOLMARK N\"\"\",\"\"\"Cortazar P and Wolmark N are co-authors of a study on breast cancer.\"\"\",6\r\n602,\"\"\"LOIBL S\"\"\",\"\"\"SALAT C\"\"\",\"\"\"Loibl S and Salat C are co-authors of a study on neoadjuvant carboplatin in early breast cancer.\"\"\",6\r\n609,\"\"\"REZAI M\"\"\",\"\"\"DENKERT C\"\"\",\"\"\"Denkert C and Rezai M are co-authors of a study on neoadjuvant carboplatin in early breast cancer.\"\"\",5\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": null}}